Customer No. 28880 MAY 2 1 2004 &

IFW

Customer No. 28880 MAY 2 1 2004	ω .		Confirmation No.
	ş ³ /	U.S. Patents are required to respond to a collection	PTO/SB/21 (P3-0T) Approved for use through 04/30/2003: OMB 0651-0031 t and Trademark Office; U.S. DEPARTMENT OF COMMERCE on of information unless it displays a valid OMB control number.
Walk		Application Number	10/811,134
TRANSMITTAL		Filing Date	MARCH 26, 2004
FORM		First Named Inventor	Cuiman Cai et al
(to be used for all correspondence after initial filin	ing)	Art Unit	
<u> </u>		Examiner Name	
Total Number of Pages in This Submission		Attorney Docket Number	PC25563A
	ENCL	OSURES (Check all that	(apply)
N	F F C C Remark	RIZATION TO CHARGE T	After Allowance Communication to a Technology Center (TC) Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Retrun Postcard Copies of all cited references except U.S. Patents THE FEE AND ANY ADDITIONAL FEES AS VERPAYMENT TO DEPOSIT ACCOUNT
SIGNATU	URE O	F APPLICANT, ATTORNE	EY, OR AGENT
Firm or Individual Signature May 17, 2004	A .	Rus	
		ATE OF TRANSMISSION	
In ereby certify that this correspondence is being facs first class mail in an envelope addressed to:Commissio	simile tran oner för Pat	smitted to the USPTO or deposited witents, P.O.Box 1450, Alexandria, VA 22313-	ith the United <u>States Postal Service with sufficient postage as</u> 1450 on this date May 17, 2004
Typed or printed Diane L. Hetzler			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date | May 17, 2004

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Signature



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT: Cuiman Cai et al EXAMINER:

SERIAL NO. : 10/811,134 ART UNIT

FILED: March 26, 2004 PAPER NO

FOR : PIPERAZINE DERIVATIVE RENIN INHIBITORS

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(b))

Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 C.F.R. §1.53(d); or before the mailing of the first Office Action on the merits.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided. Except for United States Patents and United States Patent Application Publications.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. §1.131 or otherwise, to establish that the reference(s) are not "prior art."

Consideration of the items listed is respectfully requested. Pursuant to the

10/811,134 PC25563A

provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Dated: May 17, 2004

Respectfully submitted,

Andrew J.Leon

Registration No. 46,869 Warner-Lambert Company

2800 Plymouth Road

Ann Arbor, MI 48105

Telephone: (734) 622-4047 Facsimile: (734) 622-1553



PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S.DE PARTMENT.OF COMMERCE
o a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet |1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/811,134		
Filing Date	March 26, 2004		
First Named Inventor	Cuiman Cai et al		
Art Unit			
Examiner Name			
Attornov Docket Number	DC25562A		

	1 011			DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (fkno wn)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages,C olumns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 6,051,712	04-18-2000	Hoffman-La Roche Inc	
		^{US-} 6,150,526	11-21-2000	Hoffman-La Roche Inc	
		US-			
		US-			
		US-			
-		US-			
	 	US-			

		FORE	IGN PATENT DOCL	IMENTS		
Examiner Initials*	Cite No.1	Foreign PatentD ocument	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T°
		WO03/093267 A1	11-13-2003	ACTE-LION		
		WO00/64887 A1	11-02-2000	F. HOFFMAN		
		WO02/076440 A2	10-03-2002	ELAN PHARM		
		WO00/64873 A1	11-02-2000	F. HOFFMAN		
		WO01/74796 A1	10-11-2001	Dupont Pharm		
		WO01/22964 A1	04-05-2001	Georgetown Un		

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nicind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S.DE PARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/811,134		
Filing Date	March 26, 2004		
First Named Inventor	Cuiman Cai et al		
Art Unit			
Examiner Name			
Attorney Docket Number	PC25563A		

Evemine-	Cita	Decument Number	U. S. PATENT D	Examiner Cite Document Number Publication Date Name of Patentee or Pages, C olumns, Lines, Where							
Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (fkno wn)}	MM-DD-YYYY	Applicant of Cited Document	Pages,C olumns, Lines, Where Relevant Passages or Relevant Figures Appear						
		US-		··							
		03-									
		US-									
		US-									
		US-									
		US-									
		US-									
		US-									
	-	US-									
		US-									
		US-									
		US-									
		US-	-								
		US-									
		US-									
****		US-									
		ÚS-									
		US-									
	-	US-									
		US-									

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign PatentD ocument	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	T
		WO99/65867 A1	12-23-1999	DuPont Pharm	·	
						L
						L
						Ļ
						L
						L

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S.DE PARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known		
	Application Number	10/811,134		
INFORMATION DISCLOSU	JRE Filing Date	March 26, 2004		
STATEMENT BY APPLICA	First Named Inventor	Cuiman Cai et al		
(Use as many sheets as necessary)	Art Unit			
(Use as many sneets as necessary)	Examiner Name			
Sheet 3 of 3	Attorney Docket Number	PC25563A		

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MARKI, H.P. ET AL., "Piperidine renin inhibitors: from leads to drug candidates",Il Farmaco (2001), VOL. 56, PAGES 21-27	
		OEFNER, C.; BINGGELI ET AL., "Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases?", Chemistry & Biology 1999, Vol. 6, pages 127-131	
		GULLER, R.; BINGGELI et al., "Piperidine-Renin inhibitors Compounds With Improved Pysicochemical Properties", Bioorg. Med. Chem. Lett. 1999, Vol. 9, pages 1403-1408	
		VIEIRA, E.; BINGGELI et al., "Substituted Piperidines-Highly Potent Renin Inhibitors Due To Induced Fit Adaptation of The Active Site", Bioorg. Med. Chem. Lett. 1999, Vol. 9, pages 1397-1402	
		RAHUEL, J.; RASETTI et al., "Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin", Chemistry & Biology 2000, Vol. 7, pages 493-504	
		BURSAVICH, M. G.;et al., "The Mechanism of Reations Catalysed By The Serine Beta-Lactamases", Ogr. Lett. 2001, Vol. 3, No. 15 pages 2317-2320	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.